A first-of-its-kind stem cell-based treatment for retinitis pigmentosa developed at UC Irvine has received consent from the U.S. Food & Drug Administration for use in a clinical trial.
For the better part of the last decade, a growing body of research has been revealing more and more similarities between attention-deficit/hyperactivity disorder and autism.
